NextCure Inc (NXTC) Actualités

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of...

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

Preclinical data for LNCB74 highlights its potential as therapeutic for treating multiple solid tumor...

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage...

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

Of the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results

LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-endNC410 combo with...

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage...

Form 8-K - Current report

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs...

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical...

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) --  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage...

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage...